Ultromics Secures $55M for AI Heart Failure Diagnostics

Ultromics has raised $55 million in Series C funding to expand its AI-driven heart failure diagnostics across the U.S., announced in a press release. The funding round was co-led by L&G, Allegis Capital, and Lightrock, with participation from major U.S. health systems such as UChicago Medicine's UCM Ventures and UPMC Enterprises.

Ultromics' EchoGo® platform, which is FDA-cleared and reimbursed by Medicare, is designed to detect heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. The platform uses AI to analyze echocardiograms, enabling earlier and more accurate detection of these conditions without requiring new hardware or disrupting clinical workflows.

The company plans to use the new funding to scale its technology nationwide, aiming to integrate AI-enhanced diagnostics into routine cardiac care. Ultromics has already analyzed over 430,000 echocardiograms and demonstrated improved detection rates for HFpEF compared to traditional methods. The expansion will focus on high-prevalence regions and partnerships with flagship institutions like UChicago Medicine and Mayo Clinic.